Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

<< Previous

Bullboard Posts

Next >>

Post by Fastlane2on Jul 13, 2012 3:20pm

296 Views

Post# 20112134

Yesterdays news release

I haven't seen anyone address the news release yesterday. Is anyone interpreting this differently, or are we seeing this as strictly marketing. Here is one sentence from the release.

"Skanderberg has been engaged to increase awareness of the company with analysts and other industry professionals, and to enhance the company's exposure to industry stakeholders and investors."

We know Aurizon is kicking the tires and we have all assumed that an offer may have been tendered, however Niogold maybe looking at other options. I'm surprised this news release was taken lightly.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading